- About Overview
- Honors and Awards
- Facts and Figures
- Support the School
- Contact Us
- Dean’s Office
- Dean’s Office Overview
- Education Unit
- Office of Faculty Academic Affairs
- Office of Administration
- Org Chart
- Patient Care
Sourav Bandyopadhyay, PhD
What I do
I seek to understand, at the systems level, how biological networks within cancer cells are fundamentally different from those in normal cells. Using a variety of experimental techniques, I design new platforms for the rational application of personalized medicine and the design of combination cancer therapies.
Departmental research area
Bioinformatics and Systems Biology, University of California, San Diego, 2010
Computer Science & Molecular Biology, University of Wisconsin, 2002
Sourav Bandyopadhyay obtained his PhD in Bioinformatics and Systems Biology with Trey Ideker (UC San Diego) where he made seminal contributions to our understanding of the organization and plasticity of physical and genetic interaction networks, (Bandyopadhyay et al. Science 2010, Nature Methods 2010, PLoS Computational Biology 2008). In 2010 he began an independent research career through the prestigious UCSF faculty fellowship designed to provide early independence to the world’s best scientists.
The Bandyopadhyay lab employs new cellular and molecular technologies to tackle the most urgent and clinically important problems in cancer therapy, including functional genomics, drug screens, proteomics and single cell approaches. Critically, these technologies often generate the scale and complexity of data that necessitate the development of new computational algorithms to maximize their impact and fully understand their relevance in the clinic. The lab is focused on identifying mechanisms of drug resistance and targetable synthetic lethal interactions in breast and lung cancers since these diseases are deadly in the metastatic setting and demonstrate suboptimal tumor responses even with out best, most targeted therapies. We are committed to the identification, mechanistic dissection and clinical translation of new targets and target combinations through broad collaborations with biotechnologists, chemists, clinicians and pharma.
networks, Cancer Biology, precision medicine, pathways, bioinformatics, pharmacogenomics, systems biology, pharmacogenetics, Neoplasms, Protein Interaction Mapping, Protein Kinase Inhibitors, Gene Regulatory Networks, Aurora Kinase A, Drug Resistance, Neoplasm, Breast Neoplasms, Cell Line, Tumor, Azepines, Plant Proteins, Antineoplastic Agents, Epistasis, Genetic, Synthetic Lethal Mutations, Poly(ADP-ribose) Polymerase Inhibitors